HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by HOCHBERG, F. H. Articles by ARNASON, B. G.W. Search for Related Content PubMed PubMed Citation Articles by HOCHBERG, F. H. Articles by ARNASON, B. G.W.

Herpes simplex infection and experimental allergic encephalomyelitis

An experimental model system for reactivation of EAE

Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.

The effects of herpes simplex virus type 1 (HSV-1) infection on the course of experimental allergic encephalomyelitis (EAE) were studied in rats. Fifty percent of animals given two intracerebral injections of HSV-1, one before and one after induction of EAE, showed clinical and pathologic evidence of recently exacerbated EAE 16 days after the second HSV-1 injection. When HSV-1 injections were administered subcutaneously before and after induction of EAE, 45 percent of survivors showed pathologic changes of recent EAE. A single injection intracerebrally or subcutaneously of HSV-1 given before the development of EAE did not change the clinical severity or time course of EAE. A single injection intracerebrally or subcutaneously of HSV-1 given after the development of EAE did not cause clinical recrudescence of the EAE. Pathologic but not clinical evidence of EAE recurrence was found in three of nine animals given one injection of HSV-1 intracerebrally before and one of control material intracerebrally after induction of EAE. Pathologic evidence of EAE recurrence was found in six of 14 rats given one injection of control material intracerebrally before and one of HSV-1 intracerebrally after induction of EAE. Cell suspensions, free of HSV-1, given prior and subsequent to the development of EAE did not cause a change in the EAE severity or a recrudescence of the EAE.

Dr. Lehrich's address is Department of Neurology, Massachusetts General Hospital, Boston, MA 02114.

This work was supported by fellowship number NS016741 (F.H.), by NINCDS research grant number NS09675, and by a grant from the National Multiple Sclerosis Society.

Presented in part at the twenty-sixth annual meeting of the American Academy of Neurology, San Francisco, April 1974.

Received for publication April 13, 1976.